0001615219FALSE00016152192024-06-172024-06-17

SECURITIES AND EXCHANGE COMMISSION
Washington, D.C.  20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the
Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): July 9, 2024
SALARIUS PHARMACEUTICALS, INC.
(Exact name of registrant as specified in its charter)
Delaware 001-36812 46-5087339
(State or other jurisdiction of incorporation) (Commission File Number) (IRS Employer Identification Number)
     
2450 Holcombe Blvd.
Suite X
Houston, TX
 77021
(Address of principal executive offices) (Zip Code)
(832) 834-9144
(Registrant’s telephone number, including area code)
N/A
(Former name or former address, if changed since last report)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class

Trading Symbol(s)

Name of each exchange on which registered

Common Stock, par value $0.0001
SLRX
The Nasdaq Capital Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§ 230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§ 240.12b-2 of this chapter).
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.☐


Item 8.01 Other Events.

On July 9, 2024, Salarius Pharmaceuticals, Inc. (the “Company”) was notified by researchers at The University of Texas MD Anderson Cancer Center (“MDACC”) that a patient in MDACC’s sponsored clinical trial evaluating seclidemstat (SP-2577) in combination with azacitidine in adult patients with myelodysplastic syndromes and chronic myelomonocytic leukemia experienced a serious and unexpected grade 4 adverse event. Per protocol, the U.S. Food and Drug Administration (FDA) was notified and MDACC subsequently received notification from the FDA placing the clinical trial on partial clinical hold. Under the partial clinical hold, no new patients may be enrolled at this time, but currently enrolled subjects may continue treatment and all study procedures if they are benefiting. The Company intends to support researchers at MDACC to analyze the available data and respond to questions submitted by the FDA.







SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

SALARIUS PHARMACEUTICALS, INC.
Date: July 11, 2024
By:
/s/ Mark J. Rosenblum
Mark J. Rosenblum
Chief Financial Officer
v3.24.2
Cover Page
Jun. 17, 2024
Cover [Abstract]  
Document Type 8-K
Document Period End Date Jul. 09, 2024
Entity Registrant Name SALARIUS PHARMACEUTICALS, INC.
Entity Incorporation, State or Country Code DE
Entity File Number 001-36812
Entity Tax Identification Number 46-5087339
Entity Address, Address Line Two Suite X
Entity Address, Address Line One 2450 Holcombe Blvd.
Entity Address, City or Town Houston
Entity Address, State or Province TX
Entity Address, Postal Zip Code 77021
City Area Code 832
Local Phone Number 834-9144
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, par value $0.0001
Trading Symbol SLRX
Entity Emerging Growth Company false
Entity Central Index Key 0001615219
Amendment Flag false
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
Von Jun 2024 bis Jul 2024 Click Here for more Salarius Pharmaceuticals Charts.
Salarius Pharmaceuticals (NASDAQ:SLRX)
Historical Stock Chart
Von Jul 2023 bis Jul 2024 Click Here for more Salarius Pharmaceuticals Charts.